Search results

Order by most recent / most popular / relevance

Results: 1-10 of 18

Pharmaceutical company changes policies ahead of the Bribery Act coming into force

Dorsey & Whitney LLP
-
United Kingdom
-
June 24 2011

AstraZeneca has announced that it has stopped the policy of paying for doctors to attend international medical conferences

Eli Lilly & Co

Dorsey & Whitney LLP
-
USA
-
June 24 2011

In an effort to solicit members for a class action, two law firms that represent shareholders in class actions against publicly traded companies are investigating certain officers and directors of Eli Lilly

The first company to be tried on FCPA charges is found guilty

Dorsey & Whitney LLP
-
USA
-
May 11 2011

Lindsey Manufacturing, the first company to stand trial on FCPA charges, was convicted on all counts by a jury in the Central District of California yesterday

FDA chemist charged for serial insider trading

Dorsey & Whitney LLP
-
USA
-
March 30 2011

FDA chemist Cheng Yi Liang was named as a defendant along with his son Andrew Liang in a criminal insider trading complaint

Corruption digest

Dorsey & Whitney LLP
-
Netherlands, Poland
-
July 27 2011

An internal investigation has cleared Royal Philips Electronics NV’s headquarters in the Netherlands of involvement in an alleged bribery scheme in Poland, it has been reported

Sciclone pharmaceuticals

Dorsey & Whitney LLP
-
USA
-
November 18 2011

SciClone and certain of its directors and officers have agreed to settle the consolidated derivative lawsuits that were filed following the company’s announcement that it was being investigated by the Securities and Exchange Commission (SEC) and the Department of Justice (DOJ) for possible FCPA violations

Care home inspector “requested bribes for favourable reports”

Dorsey & Whitney LLP
-
United Kingdom
-
May 17 2012

A care home inspector has been arrested by the City of London Police on suspicion of bribery and money laundering following allegations by whistleblowers that she sought bribes from care home managers to provide favourable inspection reports

Biomet Inc.

Dorsey & Whitney LLP
-
USA
-
April 16 2012

Medical device company Biomet has agreed to pay more than $22 million to settle charges by the Securities and Exchange Commission (SEC) as well as parallel criminal charges by the U.S. Department of Justice (DOJ